null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225234

Enrollment

1800

Registered

2020-06-18

Start date

2020-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : donanemab Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
safety efficacy pharmacokinetics	—

Countries

Europe, Japan, North America, Oceania

Outcome results